FDA Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 Cash Expected to Enable Company to Fund Operations through the End of 2019 PRINCETON, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported...
Dennis P. Reilly to bring commercial experience to management team Appointment Effective August 5, 2019 PRINCETON, N.J. , July 18, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Dennis P....
Meeting Scheduled for October 30, 2019 FDA Previously Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 PRINCETON, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that a meeting of the...
FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019 PRINCETON, N.J. , May 22, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the...
PRINCETON, N.J. , May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ( FDA ) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined...
PRINCETON, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari , will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22,...
PRINCETON, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla ® (AG200-15), an investigational, once weekly, low-dose hormonal contraceptive patch, will...
Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial...
PRINCETON, N.J. , March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 at...
PRINCETON, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation during the 2...
